Akums Drugs and Pharmaceuticals Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,019 Cr | 1,033 Cr | 1,010 Cr | 1,056 Cr | 1,024 Cr | 1,018 Cr | 1,160 Cr | 1,158 Cr |
| Operating expenses (approx.) | 891 Cr | 908 Cr | 884 Cr | 936 Cr | 895 Cr | 923 Cr | 1,031 Cr | 973 Cr |
| EBITDA | 128 Cr | 125 Cr | 126 Cr | 120 Cr | 129 Cr | 94 Cr | 129 Cr | 185 Cr |
| OPM % | 12.6% | 12.1% | 12.5% | 11.3% | 12.6% | 9.3% | 11.1% | 16.0% |
| Other income | 7 Cr | 13 Cr | 15 Cr | 18 Cr | 27 Cr | 32 Cr | 34 Cr | 35 Cr |
| Interest | 13 Cr | 12 Cr | 5 Cr | 5 Cr | 23 Cr | 23 Cr | 24 Cr | 24 Cr |
| Depreciation | 34 Cr | 35 Cr | 45 Cr | 40 Cr | 37 Cr | 38 Cr | 40 Cr | 40 Cr |
| Profit before tax | 87 Cr | 92 Cr | 91 Cr | 75 Cr | 96 Cr | 66 Cr | 100 Cr | 121 Cr |
| Tax % | 30.0% | 27.2% | 27.2% | -99.1% | 32.4% | 35.0% | 32.0% | 32.9% |
| Net profit | 61 Cr | 67 Cr | 66 Cr | 150 Cr | 65 Cr | 43 Cr | 68 Cr | 81 Cr |
| EPS (₹) | ₹4.21 | ₹4.37 | ₹4.26 | ₹9.64 | ₹4.15 | ₹2.66 | ₹4.33 | ₹5.53 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| Sales | 4,118 Cr | 4,359 Cr | Sign in for TTM |
| Operating expenses (approx.) | 3,585 Cr | 3,728 Cr | Sign in for TTM |
| EBITDA | 533 Cr | 631 Cr | Sign in for TTM |
| OPM % | 12.9% | 14.5% | Sign in for TTM |
| Other income | 52 Cr | 129 Cr | Sign in for TTM |
| Interest | 35 Cr | 94 Cr | Sign in for TTM |
| Depreciation | 153 Cr | 155 Cr | Sign in for TTM |
| Profit before tax | 345 Cr | 382 Cr | Sign in for TTM |
| Tax % | 0.4% | 32.9% | Sign in for TTM |
| Net profit | 344 Cr | 256 Cr | Sign in for TTM |
| EPS (₹) | ₹22.60 | ₹16.67 | Sign in for TTM |
| Dividend payout % | 0.0% | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Equity capital | 31 Cr | 31 Cr |
| Reserves | 3,033 Cr | 3,301 Cr |
| Borrowings | 14 Cr | 73 Cr |
| Other liabilities | 1,036 Cr | 2,043 Cr |
| Total liabilities | 4,113 Cr | 5,447 Cr |
| Fixed assets (net) | 1,390 Cr | 1,448 Cr |
| CWIP | 160 Cr | 177 Cr |
| Investments | 0.14 Cr | 0.14 Cr |
| Other assets | 2,275 Cr | 3,560 Cr |
| Total assets | 4,113 Cr | 5,447 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Cash from operating activity | 465 Cr | 1,181 Cr |
| Cash from investing | -548 Cr | -930 Cr |
| Cash from financing | 73 Cr | 34 Cr |
| Net cash flow | -10 Cr | 285 Cr |
| Free cash flow (OCF − Capex) | 193 Cr | 951 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| ROCE % | 12.3% | 14.0% |
| ROE % | 11.0% | 7.7% |
| Debtor days | — | — |
| Inventory days | 110 | 120 |
| Days payable | — | — |
| Cash conversion cycle | 110 | 120 |
| Debt / equity | 0.0045 | 0.02 |
| Current ratio | 2.55 | 3.25 |
| Net debt / EBITDA | -0.16 | -0.50 |
Compare with peers
Loading peers…